Skip to main content
SpringerLink
Log in

The multifaceted factor peroxisome proliferator-activated receptor γ (PPARγ) in metabolism, immunity, and cancer

  • Review
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

The consumption of high-calorie foods combined with less physical exercise has increased the prevalence of obesity. Obesity is also associated with high blood pressure, atherosclerosis, insulin resistance, diabetes, impaired host defense, and the risk of some cancers. Because PPARγ is a central player that participates in various biological responses, including lipid metabolism, inflammation, and cell proliferation, further understanding of the lipid metabolic sensor PPARγ is necessary to reduce the incidence of metabolic diseases and cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Appel, S., V. Mirakaj, A. Bringmann, M.M. Weck, F. Grunebach, and P. Brossart. 2005. PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 106(12): 3888–3894. doi:10.1182/blood-2004-12-4709.

    CAS  PubMed  Google Scholar 

  • Bae, M.A., and B.J. Song. 2003. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Molecular Pharmacology 63(2): 401–408.

    CAS  PubMed  Google Scholar 

  • Balint, B.L., and L. Nagy. 2006. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocrine, Metabolic & Immune Disorders: Drug Targets 6(1): 33–43.

    CAS  Google Scholar 

  • Barak, Y., M.C. Nelson, E.S. Ong, Y.Z. Jones, P. Ruiz-Lozano, K.R. Chien, A. Koder, and R.M. Evans. 1999. PPAR gamma is required for placental, cardiac, and adipose tissue development. Molecular Cell 4(4): 585–595. doi:10.1016/S1097-2765(00)80209-9.

    CAS  PubMed  Google Scholar 

  • Bartelt, A., and J. Heeren. 2014. Adipose tissue browning and metabolic health. Nature Reviews Endocrinology 10(1): 24–36. doi:10.1038/nrendo.2013.204.

    CAS  PubMed  Google Scholar 

  • Battaglia, S., O. Maguire, J.L. Thorne, L.B. Hornung, C.L. Doig, S. Liu, L.E. Sucheston, et al. 2010. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis 31(9): 1650–1660. doi:10.1093/carcin/bgq086.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Bonofiglio, D., S. Aquila, S. Catalano, S. Gabriele, M. Belmonte, E. Middea, H. Qi, et al. 2006. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Molecular Endocrinology 20(12): 3083–3092. doi:10.1210/me.2006-0192.

    CAS  PubMed  Google Scholar 

  • Bren-Mattison, Y., A.M. Meyer, V. Van Putten, H. Li, K. Kuhn, R. Stearman, M. Weiser-Evans, R.A. Winn, L.E. Heasley, and R.A. Nemenoff. 2008. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Molecular Pharmacology 73(3): 709–717. doi:10.1124/mol.107.042002.

    CAS  PubMed  Google Scholar 

  • Campbell, M.J., C. Carlberg, and H.P. Koeffler. 2008. A role for the PPARgamma in cancer therapy. PPAR Research 2008: 314974. doi:10.1155/2008/314974.

    PubMed Central  PubMed  Google Scholar 

  • Cesario, R.M., J. Stone, W.C. Yen, R.P. Bissonnette, and W.W. Lamph. 2006. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Letters 240(2): 225–233. doi:10.1016/j.canlet.2005.09.010.

    CAS  PubMed  Google Scholar 

  • Chawla, A., W.A. Boisvert, C.H. Lee, B.A. Laffitte, Y. Barak, S.B. Joseph, D. Liao, et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell 7(1): 161–171.

    CAS  PubMed  Google Scholar 

  • Chen, F., and L.E. Harrison. 2005. Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cellular Signalling 17(7): 809–816. doi:10.1016/j.cellsig.2004.11.002.

    CAS  PubMed  Google Scholar 

  • Choi, J.H., A.S. Banks, J.L. Estall, S. Kajimura, P. Bostrom, D. Laznik, J.L. Ruas, et al. 2010. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466(7305): 451–456. doi:10.1038/nature09291.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Choi, J.H., A.S. Banks, T.M. Kamenecka, S.A. Busby, M.J. Chalmers, N. Kumar, D.S. Kuruvilla, et al. 2011. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477(7365): 477–481. doi:10.1038/nature10383.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Cristancho, A.G., and M.A. Lazar. 2011. Forming functional fat: A growing understanding of adipocyte differentiation. Nature Reviews Molecular Cell Biology 12(11): 722–734. doi:10.1038/nrm3198.

    CAS  PubMed  Google Scholar 

  • da Rocha Junior, L.F., A.T. Dantas, A.L. Duarte, M.J. de Melo Rego, R. Pitta Ida, and M.G. Pitta. 2013. PPARgamma agonists in adaptive immunity: What do immune disorders and their models have to tell us? PPAR Research 2013: 519724. doi:10.1155/2013/519724.

    PubMed Central  PubMed  Google Scholar 

  • DePaoli, A.M., L.S. Higgins, R.R. Henry, C. Mantzoros, and F.L. Dunn. 2014. Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care 37(7): 1918–1923. doi:10.2337/dc13-2480.

    CAS  PubMed  Google Scholar 

  • Duan, S.Z., C.Y. Ivashchenko, S.E. Whitesall, L.G. D’Alecy, D.C. Duquaine, F.C. Brosius, F.J. Gonzalez, et al. 2007. Hypotension, lipodystrophy, and insulin resistance in generalized PPAR gamma-deficient mice rescued from embryonic lethality. Journal of Clinical Investigation 117(3): 812–822. doi:10.1172/Jci28859.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Erdmann, E., B. Charbonnel, and R. Wilcox. 2009. Thiazolidinediones and cardiovascular risk—a question of balance. Current Cardiology Reviews 5(3): 155–165. doi:10.2174/157340309788970333.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Farrow, B., and B.M. Evers. 2003. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 301(1): 50–53.

    CAS  PubMed  Google Scholar 

  • Feldman, P.L., M.H. Lambert, and B.R. Henke. 2008. PPAR modulators and PPAR pan agonists for metabolic diseases: The next generation of drugs targeting peroxisome proliferator-activated receptors? Current Topics in Medicinal Chemistry 8(9): 728–749.

    CAS  PubMed  Google Scholar 

  • Ferrante Jr, A.W. 2013. Macrophages, fat, and the emergence of immunometabolism. The Journal of Clinical Investigation 123(12): 4992–4993. doi:10.1172/JCI73658.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Fisher, B.L., and P. Schauer. 2002. Medical and surgical options in the treatment of severe obesity. American Journal of Surgery 184(6B): 9S–16S.

    PubMed  Google Scholar 

  • Floyd, Z.E., and J.M. Stephens. 2004. Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation. Obesity Research 12(6): 921–928. doi:10.1038/oby.2004.112.

    CAS  PubMed  Google Scholar 

  • Fredenrich, A., and P.A. Grimaldi. 2005. PPAR delta: An uncompletely known nuclear receptor. Diabetes & Metabolism 31(1): 23–27.

    CAS  Google Scholar 

  • Fujita, M., T. Yagami, M. Fujio, C. Tohji, K. Takase, Y. Yamamoto, K. Sawada, M. Yamamori, and N. Okamura. 2011. Cytotoxicity of troglitazone through PPARgamma-independent pathway and p38 MAPK pathway in renal cell carcinoma. Cancer Letters 312(2): 219–227. doi:10.1016/j.canlet.2011.08.010.

    CAS  PubMed  Google Scholar 

  • Gavrilova, O., M. Haluzik, K. Matsusue, J.J. Cutson, L. Johnson, K.R. Dietz, C.J. Nicol, C. Vinson, F.J. Gonzalez, and M.L. Reitman. 2003. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. Journal of Biological Chemistry 278(36): 34268–34276. doi:10.1074/jbc.M300043200M300043200.

    CAS  PubMed  Google Scholar 

  • Govindarajan, R., L. Ratnasinghe, D.L. Simmons, E.R. Siegel, M.V. Midathada, L. Kim, P.J. Kim, R.J. Owens, and N.P. Lang. 2007. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. Journal of Clinical Oncology 25(12): 1476–1481. doi:10.1200/JCO.2006.07.2777.

    CAS  PubMed  Google Scholar 

  • Graham, D.J., R. Ouellet-Hellstrom, T.E. MaCurdy, F. Ali, C. Sholley, C. Worrall, and J.A. Kelman. 2010. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 304(4): 411–418. doi:10.1001/jama.2010.920.

    CAS  PubMed  Google Scholar 

  • Guri, A.J., S.K. Mohapatra, W.T. Horne 2nd, R. Hontecillas, and J. Bassaganya-Riera. 2010. The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol 10: 60. doi:10.1186/1471-230X-10-60.

    PubMed Central  PubMed  Google Scholar 

  • Hammad, H., H.J. de Heer, T. Soullie, V. Angeli, F. Trottein, H.C. Hoogsteden, and B.N. Lambrecht. 2004. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. American Journal of Pathology 164(1): 263–271.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hauser, S., G. Adelmant, P. Sarraf, H.M. Wright, E. Mueller, and B.M. Spiegelman. 2000. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. Journal of Biological Chemistry 275(24): 18527–18533. doi:10.1074/jbc.M001297200M001297200.

    CAS  PubMed  Google Scholar 

  • He, W., Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J.M. Olefsky, and R.M. Evans. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proceedings of the National Academy of Sciences USA 100(26): 15712–15717. doi:10.1073/pnas.2536828100.

    CAS  Google Scholar 

  • Hevener, A.L., W.M. He, Y. Barak, J. Le, G. Bandyopadhyay, P. Olson, J. Wilkes, R.M. Evans, and J. Olefsky. 2003. Muscle-specific Pparg deletion causes insulin resistance. Nature Medicine 9(12): 1491–1497. doi:10.1038/Nm956.

    CAS  PubMed  Google Scholar 

  • Hill, J.O., H.R. Wyatt, G.W. Reed, and J.C. Peters. 2003. Obesity and the environment: where do we go from here? Science 299(5608): 853–855. doi:10.1126/science.1079857299/5608/853.

    CAS  PubMed  Google Scholar 

  • Hong, J.W., and K.W. Park. 2010. Further understanding of fat biology: lessons from a fat fly. Experimental & Molecular Medicine 42(1): 12–20. doi:10.3858/emm.2010.42.1.007.

    CAS  Google Scholar 

  • Hontecillas, R., and J. Bassaganya-Riera. 2007. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. The Journal of Immunology 178(5): 2940–2949.

    CAS  PubMed  Google Scholar 

  • Hwa, J.S., L. Mun, H.J. Kim, H.G. Seo, J.H. Lee, J.H. Kwak, D.U. Lee, and K.C. Chang. 2011. Genipin selectively inhibits TNF-alpha-activated VCAM-1 but not ICAM-1 expression by upregulation of PPAR-gamma in human endothelial cells. Korean Journal of Physiology and Pharmacology 15(3): 157–162. doi:10.4196/kjpp.2011.15.3.157.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Jeong, Y., Y. Xie, W. Lee, A.L. Bookout, L. Girard, G. Raso, C. Behrens, et al. 2012. Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Molecular Endocrinology 26(8): 1443–1454. doi:10.1210/me.2011-1382.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Jones, J.R., C. Barrick, K.A. Kim, J. Lindner, B. Blondeau, Y. Fujimoto, M. Shiota, R.A. Kesterson, B.B. Kahn, and M.A. Magnuson. 2005. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. The Proceedings of the National Academy USA 102(17): 6207–6212. doi:10.1073/pnas.0306743102.

    CAS  Google Scholar 

  • Kebebew, E., Peng, M., Reiff, E., Treseler, P., Woeber, K., Clark, O.H., Greenspan, F.S., Lindsay, S., Duh, Q.Y., and Morita, E. 2006. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140 (6):960–966. Discussion 966–967. doi:10.1016/j.surg.2006.07.038.

  • Kidani, Y., and S.J. Bensinger. 2012. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunological Reviews 249(1): 72–83. doi:10.1111/j.1600-065X.2012.01153.x.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kilroy, G.E., X. Zhang, and Z.E. Floyd. 2009. PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal. Obesity (Silver Spring) 17(4): 665–673. doi:10.1038/oby.2008.616.

    CAS  Google Scholar 

  • Kilroy, G., H. Kirk-Ballard, L.E. Carter, and Z.E. Floyd. 2012. The ubiquitin ligase Siah2 regulates PPARgamma activity in adipocytes. Endocrinology 153(3): 1206–1218. doi:10.1210/en.2011-1725.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kim, J.H., K.W. Park, E.W. Lee, W.S. Jang, J. Seo, S. Shin, K.A. Hwang, and J. Song. 2014. Suppression of PPARgamma through MKRN1-mediated ubiquitination and degradation prevents adipocyte differentiation. Cell Death and Differentiation 21(4): 594–603. doi:10.1038/cdd.2013.181.

    CAS  PubMed  Google Scholar 

  • Kim, K.Y., S.S. Kim, and H.G. Cheon. 2006. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochemical Pharmacology 72(5): 530–540. doi:10.1016/j.bcp.2006.05.009.

    CAS  PubMed  Google Scholar 

  • Kim, Y., N. Suh, M. Sporn, and J.C. Reed. 2002. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. Journal of Biological Chemistry 277(25): 22320–22329. doi:10.1074/jbc.M202458200.

    CAS  PubMed  Google Scholar 

  • Kiss, M., Z. Czimmerer, and L. Nagy. 2013. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology. The Journal of Allergy and Clinical Immunology 132(2): 264–286. doi:10.1016/j.jaci.2013.05.044.

    CAS  PubMed  Google Scholar 

  • Klotz, L., S. Burgdorf, I. Dani, K. Saijo, J. Flossdorf, S. Hucke, J. Alferink, et al. 2009. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. Journal of Experimental Medicine 206(10): 2079–2089. doi:10.1084/jem.20082771.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Koeffler, H.P. 2003. Peroxisome proliferator-activated receptor gamma and cancers. Clinical Cancer Research 9(1): 1–9.

    CAS  PubMed  Google Scholar 

  • Kopelman, P.G. 2000. Obesity as a medical problem. Nature 404(6778): 635–643. doi:10.1038/35007508.

    CAS  PubMed  Google Scholar 

  • Lehmann, J.M., L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). Journal of Biological Chemistry 270(22): 12953–12956.

    CAS  PubMed  Google Scholar 

  • Liu, Y., Z.A. Zhu, S.N. Zhang, J. Mou, L. Liu, T. Cui, and D.S. Pei. 2013. Combinational effect of PPARgamma agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro. Tumour Biology 34(4): 2409–2418. doi:10.1007/s13277-013-0791-2.

    CAS  PubMed  Google Scholar 

  • Lubet, R.A., S.M. Fischer, V.E. Steele, M.M. Juliana, R. Desmond, and C.J. Grubbs. 2008. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. International Journal of Cancer 123(10): 2254–2259. doi:10.1002/ijc.23765.

    CAS  Google Scholar 

  • Manolagas, S.C. 1998. Cellular and molecular mechanisms of osteoporosis. Aging (Milano) 10(3): 182–190.

    CAS  Google Scholar 

  • Mansure, J.J., R. Nassim, S. Chevalier, K. Szymanski, J. Rocha, S. Aldousari, and W. Kassouf. 2013. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. PLoS ONE 8(2): e55997. doi:10.1371/journal.pone.0055997.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Matsusue, K., M. Haluzik, G. Lambert, S.H. Yim, O. Gavrilova, J.M. Ward, B. Brewer Jr, M.L. Reitman, and F.J. Gonzalez. 2003. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. Journal of Clinical Investigation 111(5): 737–747. doi:10.1172/JCI17223.

    PubMed Central  CAS  PubMed  Google Scholar 

  • McAlpine, C.A., Y. Barak, I. Matise, and R.T. Cormier. 2006. Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. International Journal of Cancer 119(10): 2339–2346. doi:10.1002/ijc.22115.

    CAS  Google Scholar 

  • McKinnon, B., N.A. Bersinger, and M.D. Mueller. 2012. Peroxisome proliferating activating receptor gamma-independent attenuation of interleukin 6 and interleukin 8 secretion from primary endometrial stromal cells by thiazolidinediones. Fertility and Sterility 97(3): 657–664. doi:10.1016/j.fertnstert.2011.12.001.

    CAS  PubMed  Google Scholar 

  • Moerman, E.J., K. Teng, D.A. Lipschitz, and B. Lecka-Czernik. 2004. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 3(6): 379–389. doi:10.1111/j.1474-9728.2004.00127.x.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Motomura, W., T. Okumura, N. Takahashi, T. Obara, and Y. Kohgo. 2000. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Research 60(19): 5558–5564.

    CAS  PubMed  Google Scholar 

  • Mueller, E., M. Smith, P. Sarraf, T. Kroll, A. Aiyer, D.S. Kaufman, W. Oh, et al. 2000. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. The Proceedings of the National Academy USA 97(20): 10990–10995. doi:10.1073/pnas.180329197.

    CAS  Google Scholar 

  • Nagy, L., P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93(2): 229–240.

    CAS  PubMed  Google Scholar 

  • Nencioni, A., F. Grunebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart. 2002. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. Journal of Immunology 169(3): 1228–1235.

    CAS  Google Scholar 

  • Nesto, R.W., D. Bell, R.O. Bonow, V. Fonseca, S.M. Grundy, E.S. Horton, M. Le Winter, et al. 2004. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27(1): 256–263.

    CAS  PubMed  Google Scholar 

  • Nguyen, M.T., A. Chen, W.J. Lu, W. Fan, P.P. Li, D.Y. Oh, and D. Patsouris. 2012. Regulation of chemokine and chemokine receptor expression by PPARgamma in adipocytes and macrophages. PLoS ONE 7(4): e34976. doi:10.1371/journal.pone.0034976.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Nissen, S.E., and K. Wolski. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356(24): 2457–2471. doi:10.1056/NEJMoa072761.

    CAS  PubMed  Google Scholar 

  • Norris, A.W., L. Chen, S.J. Fisher, I. Szanto, M. Ristow, A.C. Jozsi, M.F. Hirshman, et al. 2003. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. Journal of Clinical Investigation 112(4): 608–618. doi:10.1172/JCI17305.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Odegaard, J.I., and A. Chawla. 2011. Alternative macrophage activation and metabolism. Annual Review of Pathology: Mechanisms of Disease 6: 275–297. doi:10.1146/annurev-pathol-011110-130138.

    CAS  Google Scholar 

  • Odegaard, J.I., R.R. Ricardo-Gonzalez, M.H. Goforth, C.R. Morel, V. Subramanian, L. Mukundan, A. Red Eagle, et al. 2007. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447(7148): 1116–1120. doi:10.1038/nature05894.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ogino, S., K. Shima, Y. Baba, K. Nosho, N. Irahara, S. Kure, L. Chen, et al. 2009. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136(4): 1242–1250. doi:10.1053/j.gastro.2008.12.048.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Park, K.W., D.S. Halperin, and P. Tontonoz. 2008a. Before they were fat: adipocyte progenitors. Cell Metabolism 8(6): 454–457. doi:10.1016/j.cmet.2008.11.001.

    CAS  PubMed  Google Scholar 

  • Park, K.W., H. Waki, S.P. Choi, K.M. Park, and P. Tontonoz. 2010. The small molecule phenamil is a modulator of adipocyte differentiation and PPARgamma expression. Journal of Lipid Research 51(9): 2775–2784. doi:10.1194/jlr.M008490.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Park, K.W., H. Waki, C.J. Villanueva, L.A. Monticelli, C. Hong, S. Kang, O.A. MacDougald, A.W. Goldrath, and P. Tontonoz. 2008b. Inhibitor of DNA binding 2 is a small molecule-inducible modulator of peroxisome proliferator-activated receptor-gamma expression and adipocyte differentiation. Molecular Endocrinology 22(9): 2038–2048. doi:10.1210/me.2007-0454.

    CAS  PubMed  Google Scholar 

  • Park, S.J., F. Ahmad, A. Philp, K. Baar, T. Williams, H. Luo, H. Ke, et al. 2012. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148(3): 421–433. doi:10.1016/j.cell.2012.01.017.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Pascual, G., A.L. Fong, S. Ogawa, A. Gamliel, A.C. Li, V. Perissi, D.W. Rose, T.M. Willson, M.G. Rosenfeld, and C.K. Glass. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437(7059): 759–763. doi:10.1038/nature03988.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Peirce, V., S. Carobbio, and A. Vidal-Puig. 2014. The different shades of fat. Nature 510(7503): 76–83. doi:10.1038/nature13477.

    CAS  PubMed  Google Scholar 

  • Pi-Sunyer, X. 2003. A clinical view of the obesity problem. Science 299(5608): 859–860. doi:10.1126/science.1082319299/5608/859.

    CAS  PubMed  Google Scholar 

  • Picard, F., M. Kurtev, N. Chung, A. Topark-Ngarm, T. Senawong, R. Machado De Oliveira, M. Leid, M.W. McBurney, and L. Guarente. 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429(6993): 771–776. doi:10.1038/nature02583nature02583.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Qiu, Y., K.D. Nguyen, J.I. Odegaard, X. Cui, X. Tian, R.M. Locksley, R.D. Palmiter, and A. Chawla. 2014. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 157(6): 1292–1308. doi:10.1016/j.cell.2014.03.066.

    CAS  PubMed  Google Scholar 

  • Quintanilla, R.A., E. Utreras, and F.A. Cabezas-Opazo. 2014. Role of PPAR gamma in the differentiation and function of neurons. PPAR Research 2014: 768594. doi:10.1155/2014/768594.

    PubMed Central  PubMed  Google Scholar 

  • Ramkalawan, H., Y.Z. Wang, A. Hurbungs, Y.F. Yang, F.F. Tian, W.B. Zhou, J. Li, H. Yang, B. Xiao, and W. Zhang. 2012. Pioglitazone, PPARgamma agonist, attenuates experimental autoimmune neuritis. Inflammation 35(4): 1338–1347. doi:10.1007/s10753-012-9447-4.

    CAS  PubMed  Google Scholar 

  • Ramos-Nino, M.E., C.D. MacLean, and B. Littenberg. 2007. Association between cancer prevalence and use of thiazolidinediones: results from the vermont diabetes information system. BMC Medicine 5: 17. doi:10.1186/1741-7015-5-17.

    PubMed Central  PubMed  Google Scholar 

  • Ricote, M., A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391(6662): 79–82. doi:10.1038/34178.

    CAS  PubMed  Google Scholar 

  • Saez, E., P. Tontonoz, M.C. Nelson, J.G. Alvarez, U.T. Ming, S.M. Baird, V.A. Thomazy, and R.M. Evans. 1998. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nature Medicine 4(9): 1058–1061. doi:10.1038/2042.

    CAS  PubMed  Google Scholar 

  • Sharma, C., A. Pradeep, L. Wong, A. Rana, and B. Rana. 2004. Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. Journal of Biological Chemistry 279(34): 35583–35594. doi:10.1074/jbc.M403143200.

    CAS  PubMed  Google Scholar 

  • Shiau, C.W., C.C. Yang, S.K. Kulp, K.F. Chen, C.S. Chen, J.W. Huang, and C.S. Chen. 2005. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Research 65(4): 1561–1569. doi:10.1158/0008-5472.CAN-04-1677.

    CAS  PubMed  Google Scholar 

  • Shoelson, S.E., J. Lee, and M. Yuan. 2003. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. International Journal of Obesity and Related Metabolic Disorders 27(Suppl 3): S49–S52. doi:10.1038/sj.ijo.08025010802501.

    CAS  PubMed  Google Scholar 

  • Sikka, S., L. Chen, G. Sethi, and A.P. Kumar. 2012. Targeting PPARgamma signaling cascade for the prevention and treatment of prostate cancer. PPAR Research 2012: 968040. doi:10.1155/2012/968040.

    PubMed Central  PubMed  Google Scholar 

  • Sims, N.A., and J.H. Gooi. 2008. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Seminars in Cell & Developmental Biology 19(5): 444–451. doi:10.1016/j.semcdb.2008.07.016.

    CAS  Google Scholar 

  • Skelhorne-Gross, G., and C.J. Nicol. 2012. The key to unlocking the chemotherapeutic potential of ppargamma ligands: Having the right combination. PPAR Research 2012: 946943. doi:10.1155/2012/946943.

    PubMed Central  PubMed  Google Scholar 

  • Skelhorne-Gross, G., A.L. Reid, A.J. Apostoli, M.A. Di Lena, R.E. Rubino, N.T. Peterson, M. Schneider, S.K. SenGupta, F.J. Gonzalez, and C.J. Nicol. 2012. Stromal adipocyte PPARgamma protects against breast tumorigenesis. Carcinogenesis 33(7): 1412–1420. doi:10.1093/carcin/bgs173.

    CAS  PubMed  Google Scholar 

  • Straus, D.S., and C.K. Glass. 2007. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends in Immunology 28(12): 551–558. doi:10.1016/j.it.2007.09.003.

    CAS  PubMed  Google Scholar 

  • Szanto, A., and L. Nagy. 2008. The many faces of PPARgamma: Anti-inflammatory by any means? Immunobiology 213(9–10): 789–803. doi:10.1016/j.imbio.2008.07.015.

    CAS  PubMed  Google Scholar 

  • Szatmari, I., E. Rajnavolgyi, and L. Nagy. 2006. PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function. Annals of the New York Academy of Sciences 1088: 207–218. doi:10.1196/annals.1366.013.

    CAS  PubMed  Google Scholar 

  • Tontonoz, P., L. Nagy, J.G. Alvarez, V.A. Thomazy, and R.M. Evans. 1998. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93(2): 241–252.

    CAS  PubMed  Google Scholar 

  • Tontonoz, P., and B.M. Spiegelman. 2008. Fat and beyond: The diverse biology of PPARgamma. Annual Review of Biochemistry 77: 289–312. doi:10.1146/annurev.biochem.77.061307.091829.

    CAS  PubMed  Google Scholar 

  • Turner, N., G.J. Cooney, E.W. Kraegen, and C.R. Bruce. 2014. Fatty acid metabolism, energy expenditure and insulin resistance in muscle. Journal of Endocrinology 220(2): T61–T79. doi:10.1530/JOE-13-0397.

    CAS  PubMed  Google Scholar 

  • van Beekum, O., V. Fleskens, and E. Kalkhoven. 2009. Posttranslational modifications of PPAR-gamma: Fine-tuning the metabolic master regulator. Obesity (Silver Spring) 17(2): 213–219. doi:10.1038/oby.2008.473.

    Google Scholar 

  • van Raalte, D.H., M. Li, P.H. Pritchard, and K.M. Wasan. 2004. Peroxisome proliferator-activated receptor (PPAR)-alpha: A pharmacological target with a promising future. Pharmaceutical Research 21(9): 1531–1538.

    PubMed  Google Scholar 

  • Vitale, G., S. Zappavigna, M. Marra, A. Dicitore, S. Meschini, M. Condello, G. Arancia, et al. 2012. The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. Biotechnology Advances 30(1): 169–184. doi:10.1016/j.biotechadv.2011.08.001.

    CAS  PubMed  Google Scholar 

  • Waki, H., K.W. Park, N. Mitro, L. Pei, R. Damoiseaux, D.C. Wilpitz, K. Reue, E. Saez, and P. Tontonoz. 2007. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. Cell Metabolism 5(5): 357–370. doi:10.1016/j.cmet.2007.03.010.

    CAS  PubMed  Google Scholar 

  • Waki, H., and P. Tontonoz. 2007. Endocrine functions of adipose tissue. Annual Review of Pathology: Mechanisms of Disease 2: 31–56. doi:10.1146/annurev.pathol.2.010506.091859.

    CAS  Google Scholar 

  • Wang, C.Z., Y. Zhang, X.D. Li, Y. Hu, Z.G. Fang, D.J. Lin, R.Z. Xiao, et al. 2011. PPARgamma agonist suppresses TLR4 expression and TNF-alpha production in LPS stimulated monocyte leukemia cells. Cell Biochemistry and Biophysics 60(3): 167–172. doi:10.1007/s12013-010-9136-6.

    CAS  PubMed  Google Scholar 

  • Wang, F., S.E. Mullican, J.R. DiSpirito, L.C. Peed, and M.A. Lazar. 2013. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARgamma. The Proceedings of the National Academy USA 110(46): 18656–18661. doi:10.1073/pnas.1314863110.

    CAS  Google Scholar 

  • Wang, L., B. Waltenberger, E.M. Pferschy-Wenzig, M. Blunder, X. Liu, C. Malainer, T. Blazevic, et al. 2014a. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): A review. Biochemical Pharmacology. doi:10.1016/j.bcp.2014.07.018.

    Google Scholar 

  • Wang, S., N. Moustaid-Moussa, L. Chen, H. Mo, A. Shastri, R. Su, P. Bapat, I. Kwun, and C.L. Shen. 2014b. Novel insights of dietary polyphenols and obesity. Journal of Nutritional Biochemistry 25(1): 1–18. doi:10.1016/j.jnutbio.2013.09.001.

    PubMed Central  PubMed  Google Scholar 

  • Wei, S., L.F. Lin, C.C. Yang, Y.C. Wang, G.D. Chang, H. Chen, and C.S. Chen. 2007. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma. Molecular Pharmacology 72(3): 725–733. doi:10.1124/mol.107.035287.

    CAS  PubMed  Google Scholar 

  • Weisberg, S.P., D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, and A.W. Ferrante Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation 112(12): 1796–1808. doi:10.1172/JCI19246112/12/1796.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Wernstedt Asterholm, I., C. Tao, T.S. Morley, Q.A. Wang, F. Delgado-Lopez, Z.V. Wang, and P.E. Scherer. 2014. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metabolism 20(1): 103–118. doi:10.1016/j.cmet.2014.05.005.

    CAS  PubMed  Google Scholar 

  • Xu, H., G.T. Barnes, Q. Yang, G. Tan, D. Yang, C.J. Chou, J. Sole, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. The Journal of Clinical Investigation 112(12): 1821–1830. doi:10.1172/JCI19451112/12/1821.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yach, D., D. Stuckler, and K.D. Brownell. 2006. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nature Medicine 12(1): 62–66. doi:10.1038/nm0106-62.

    CAS  PubMed  Google Scholar 

  • Yan, K.H., C.J. Yao, H.Y. Chang, G.M. Lai, A.L. Cheng, and S.E. Chuang. 2010. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Molecular Carcinogenesis 49(3): 235–246. doi:10.1002/mc.20593.

    CAS  PubMed  Google Scholar 

  • Yin, F., S. Wakino, Z. Liu, S. Kim, W.A. Hsueh, A.R. Collins, A.J. Van Herle, and R.E. Law. 2001. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochemical and Biophysical Research Communications 286(5): 916–922. doi:10.1006/bbrc.2001.5491.

    CAS  PubMed  Google Scholar 

  • Yu, S., K. Matsusue, P. Kashireddy, W.Q. Cao, V. Yeldandi, A.V. Yeldandi, M.S. Rao, F.J. Gonzalez, and J.K. Reddy. 2003. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. Journal of Biological Chemistry 278(1): 498–505. doi:10.1074/jbc.M210062200M210062200.

    CAS  PubMed  Google Scholar 

  • Zander, T., J.A. Kraus, C. Grommes, U. Schlegel, D. Feinstein, T. Klockgether, G. Landreth, J. Koenigsknecht, and M.T. Heneka. 2002. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. Journal of Neurochemistry 81(5): 1052–1060.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (NRF-2013R1A1A2060447), by the National Research Foundation of Korea (NRF) funded by the Korean government (MEST) (2010-0017787), by the National Cancer Center, Korea (NCC-1420300), and by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare of the Republic of Korea (HI12C1280).

Author information

Authors and Affiliations

  1. Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, Seoul, 120-749, Korea

    Jung-Hoon Kim & Jaewhan Song

  2. Department of Food Science and Biotechnology, College of Biotechnology and Biotechnology, Sungkyunkwan University, Suwon, 440-746, Gyeonggi-do, Korea

    Kye Won Park

Authors
  1. Jung-Hoon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaewhan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kye Won Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jaewhan Song or Kye Won Park.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, JH., Song, J. & Park, K.W. The multifaceted factor peroxisome proliferator-activated receptor γ (PPARγ) in metabolism, immunity, and cancer. Arch. Pharm. Res. 38, 302–312 (2015). https://doi.org/10.1007/s12272-015-0559-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-015-0559-x

Keywords

Search

Navigation